{"id":3145,"date":"2015-02-05T07:30:00","date_gmt":"2015-02-05T07:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/"},"modified":"2015-02-05T07:30:00","modified_gmt":"2015-02-05T07:30:00","slug":"strong-growth-and-doubled-ebitda-exklusive-one-time-expenses","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/","title":{"rendered":"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES"},"content":{"rendered":"<\/p>\n

FOURTH QUARTER 2014 (OCT – DEC)<\/span><\/p>\n<\/p>\n

\u00a0\u2022 Net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding to an increase of 28 percent.<\/span>
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 5.9 (3.0) million, corresponding to an EBITDA margin of 23 percent. One-time expenses of SEK 2.8 million related to the dispute regarding three Vivoline patents\/patent applications have been charged against the quarter.<\/span>
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.1 (3.0) million, corresponding to an EBITDA margin of 12 percent. <\/span>
\u2022 Net income amounted to SEK -0.3 (2.4) million, resulting in earnings per share of SEK -0.01 (0.12). <\/span>
\u2022 Cash flow from operating activities was SEK -5.4 (7.1) million due to increased working capital effecting cash flow by -7.8 SEK million.<\/span>
\u2022 Net sales for consumables in the quarter amounted to SEK 25.5 (20.0) million, corresponding to an increase of 28 percent in SEK. Sales for consumables increased by 17 percent in local currency.<\/span>
\u2022 Products for warm perfusion (STEEN Solution\u2122 and products related to the use of the XPS\u2122) accounted for 34 (21) percent of the total sales of consumables.<\/span>
\u2022 Two XPS\u2122 contracts were signed during the quarter.<\/span>
\u2022 XVIVO has received Vinnova financing for cancer research in Europe.<\/span>
\u2022 The Arbitration Board ruled that XVIVO does not have agreement rights to three Vivoline patents\/patent applications, pursuant to the improvement clause in the current agreement that the company has with Igel\u00f6sa. The company\u2019s own products, STEEN Solution\u2122, which is protected by patents that are valid until 2021, and Perfadex\u00ae<\/sup> are not part of the dispute.<\/span><\/p>\n<\/p>\n

THE PERIOD 2014 (JAN \u2013 DEC)<\/span><\/p>\n<\/p>\n

\u00a0\u2022 Net sales in the period amounted to SEK 84.7 (68.9) million, corresponding to an increase of 23 percent.<\/span>
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 15.7 (13.0) million, corresponding to an EBITDA margin of 19 percent. One-time expenses of SEK 4.3 million related to the dispute regarding three Vivoline patents\/patent applications have been charged against the period.<\/span>
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 11.4 (13.0) million, corresponding to an EBITDA margin of 13 percent. <\/span>
\u2022 Net income amounted to SEK 3.7 (8.1) million, resulting in earnings per share of SEK 0.18 (0.41). <\/span>
\u2022 Cash flow from operating activities was SEK -3.7 (13.5) million and was affected by increased working capital of -10.5 SEK million and paid taxes of SEK -4.6 million.<\/span>
\u2022 Net sales for consumables in the period amounted to SEK 83.2 (68.9) million, corresponding to an increase of 21 percent in SEK. Sales for consumables increased by 15 percent in local currency.<\/span>
\u2022 Products for warm perfusion (STEEN Solution\u2122 and products related to the use of the XPS\u2122) accounted for 27 (16) percent of the total sales of consumables. <\/span>
\u2022 XPS\u2122 (Xvivo Perfusion System) received a CE mark, allowing XPS\u2122 and the accompanying single-use products to be sold in Europe.<\/span>
\u2022 The FDA granted marketing approval for XPS\u2122 and STEEN Solution\u2122, allowing STEEN Solution\u2122, XPS\u2122 and the accompanying single-use products to be sold in the US.<\/span>
\u2022 XVIVO Perfusion completed a share issue through a private placement of SEK 73 million.<\/span><\/p>\n<\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER<\/span><\/p>\n<\/p>\n

\u00a0\u2022 Two XPS\u2122 contracts were signed after the end of the quarter in addition to the twp contracts signed during quarter four.<\/span><\/p>\n<\/p>\n

CONFERENCE CALL<\/span><\/p>\n<\/p>\n

\u00a0CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, February 5, 2015. Telephone: +44 (0) 1452 555566, enter code 56175829.<\/span><\/p>\n<\/p>\n

February 5, 2015
Gothenburg <\/span><\/p>\n

XVIVO Perfusion AB (publ)
<\/span>Magnus Nilsson, CEO<\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0February 5, 2015\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOURTH QUARTER 2014 (OCT – DEC) \u00a0\u2022 Net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding to…<\/p>\n","protected":false},"template":"","class_list":["post-3145","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q4"],"acf":[],"yoast_head":"\nSTRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES - XVIVO\" \/>\n<meta property=\"og:description\" content=\"FOURTH QUARTER 2014 (OCT – DEC) \u00a0\u2022 Net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\\\/\",\"name\":\"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-02-05T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/","og_locale":"en_US","og_type":"article","og_title":"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES - XVIVO","og_description":"FOURTH QUARTER 2014 (OCT – DEC) \u00a0\u2022 Net sales in the quarter amounted to SEK 25.5 (20.0) million, corresponding to...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/","name":"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-02-05T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/strong-growth-and-doubled-ebitda-exklusive-one-time-expenses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"STRONG GROWTH AND DOUBLED EBITDA EXKLUSIVE ONE-TIME EXPENSES"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}